A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies

Morris D. Groves, Michael J. Glantz, Marc C. Chamberlain, Karen E. Baumgartner, Charles A. Conrad, Sigmund Hsu, Jeffrey S. Wefel, Mark R. Gilbert, Sandra Ictech, Kathy U. Hunter, Arthur D. Forman, Vinay K. Puduvalli, Howard Colman, Kenneth R. Hess, W. K.Alfred Yung

Research output: Contribution to journalArticle

77 Scopus citations

Abstract

To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of intraventricular (IVent) topotecan in patients with neoplastic meningitis (NM), we conducted a phase II, open-label, nonran-domized, single-arm trial of IVent topotecan in patients with NM using 400 μg of topotecan IVent twice weekly for 6 weeks, followed by evaluation with imaging, cere-brospinal fluid (CSF), and physical examinations. In the absence of disease progression, patients were then treated with IVent topotecan weekly for 6 weeks, twice monthly for 4 months, and monthly thereafter. Sixty-two patients (23 males and 39 females) were enrolled from April 2001 through March 2006. Median age and KPS at enrollment were 56 (range 5-83) and 80 (range 60-100), respectively. Primary cancers included breast (19), lung (13), CNS (14), and others (16). Forty patients (65%) completed the 6-week induction period, among whom 13 (21%) had CSF clearance of malignant cells. Kaplan-Meier estimates of PFS at 13 and 26 weeks were 30% (95% confidence interval [CI], 20%-45%) and 19% (95% CI, 11%-34%). Overall median survival (50 deaths) was 15 weeks (95% CI, 13-24 weeks). The most common side effect was chemical meningitis in 32% of patients (5% grade 3); 32% experienced no drug side effects. IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered.

Original languageEnglish (US)
Pages (from-to)208-215
Number of pages8
JournalNeuro-oncology
Volume10
Issue number2
DOIs
StatePublished - Apr 2008

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies'. Together they form a unique fingerprint.

  • Cite this

    Groves, M. D., Glantz, M. J., Chamberlain, M. C., Baumgartner, K. E., Conrad, C. A., Hsu, S., Wefel, J. S., Gilbert, M. R., Ictech, S., Hunter, K. U., Forman, A. D., Puduvalli, V. K., Colman, H., Hess, K. R., & Yung, W. K. A. (2008). A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-oncology, 10(2), 208-215. https://doi.org/10.1215/15228517-2007-059